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Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but  there are 
only  few  reports  on  chronic  myelomonocycitic  (CMML)  leukemia  patients.  We  describe  our 
experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response 
after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable 
peripheral blood counts, at 29 and 30 cycles from treatment start. 
Introduction: Chronic  myelomonocytic  leukemia 
(CMML)  is  a  clonal  disorder  of  hematopoietic  stem 
cells often  occurring  in  elderly  patients.  It  was 
originally  classified  by  the  French-American
(FAB) working group as a myelodysplastic syndrome 
characterized  by  monocytosis  (>  1000/microl),  bone 
marrow monocyte infiltration, blast cells less than 5% 
in the peripheral blood and less than 30% in the bone 
marrow.
1 In  the  new  WHO  classification  system  of 
tumors of hematopoietic and lymphoid tissues, CMML 
has  been  reclassified  as  a 
myelodysplastic/myeloproliferative diseases,  a  hybrid 
disorder characterized by proliferation of the myeloid 
series  and  dysplasia  of  erythroid-
series.  CMML  has  been  subdivided  in  the  WHO 
classification in two subclasses according to prognosis, 
blood and bone marrow blast count: CMML
blasts  and 5-9% blasts  in peripheral blood and bone 
marrow, respectively, and CMML-2: <10% blasts and 
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Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but  there are 
myelomonocycitic  (CMML)  leukemia  patients.  We  describe  our 
experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response 
after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable 
peripheral blood counts, at 29 and 30 cycles from treatment start. 
Chronic  myelomonocytic  leukemia 
(CMML)  is  a  clonal  disorder  of  hematopoietic  stem 
often  occurring  in  elderly  patients.  It  was 
American-British 
(FAB) working group as a myelodysplastic syndrome 
characterized  by  monocytosis  (>  1000/microl),  bone 
marrow monocyte infiltration, blast cells less than 5% 
the peripheral blood and less than 30% in the bone 
In  the  new  WHO  classification  system  of 
tumors of hematopoietic and lymphoid tissues, CMML 
has  been  reclassified  as  a 
diseases,  a  hybrid 
disorder characterized by proliferation of the myeloid 
-megakaryocytic 
series.  CMML  has  been  subdivided  in  the  WHO 
classification in two subclasses according to prognosis, 
nt: CMML-1: <5% 
9% blasts  in peripheral blood and bone 
2: <10% blasts and 
10-19% blasts in peripheral blood and bone marrow, 
respectively.
2
CMML  is  a  very  hard  disease  to  treat  and  the 
prognosis is quite variable, with a median survival of 
about 20 months. Patients elderly age and comorbidites 
impact  on  survival,  making  bone  marrow 
transplantation  only  rarely  possible.  Patients  are 
usually  treated  with  supportive  care  or  mild 
cytoreductive  therapy,  like  hydroxyure
cytarabine,  until  leukemic  evolution.  In  the  era  of 
epigenetics,  the  possibilities  offered  by  the  new 
molecular  targeted  therapies  offer  the  chance  of 
modifying the natural history of this disease. Among 
these,  the  hypomethylating  agents  Azac
Decitabine  have  been  shown  to  induce  responses  in 
CMML  patients.  Azacytidine  is  mostly  incorporated 
into  RNA  and  reaches  DNA  following  reduction  by 
ribonucleotide  reductase,  while  decitabine  is  directly 
incorporated into DNA. Both drugs have be
to produce a direct decrease of DNA methyltransferase 
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CMML  is  a  very  hard  disease  to  treat  and  the 
, with a median survival of 
about 20 months. Patients elderly age and comorbidites 
impact  on  survival,  making  bone  marrow 
transplantation  only  rarely  possible.  Patients  are 
usually  treated  with  supportive  care  or  mild 
cytoreductive  therapy,  like  hydroxyurea  or  low  dose 
cytarabine,  until  leukemic  evolution.  In  the  era  of 
epigenetics,  the  possibilities  offered  by  the  new 
molecular  targeted  therapies  offer  the  chance  of 
modifying the natural history of this disease. Among 
these,  the  hypomethylating  agents  Azacitidine  and 
Decitabine  have  been  shown  to  induce  responses  in 
CMML  patients.  Azacytidine  is  mostly  incorporated 
into  RNA  and  reaches  DNA  following  reduction  by 
ribonucleotide  reductase,  while  decitabine  is  directly 
incorporated into DNA. Both drugs have been shown 
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Table 1. Patients’ Characteristics 
Patient 1 Patient 2 Patient 3
Counts at diagnosis
Hb (g/dl)
WBC (10
9/L)
Monocytes (10
9/L)
PLTS (10
9/L)
BM-blasts (%)
9.9
19.4
6.5
55
11
12
10.5
3
77
15
8
9.4
4
178
9
Counts after 4 AZA cycles
Hb (g/dl)
WBC (10
9/L)
Monocytes (10
9/L)
PLTS (10
9/L)
BM-blasts (%)
13.3
7.09
0.68
86
2.5
11.2
6.03
1.03
84
3.5
Progression
Counts after 8 AZA cycles
Hb (g/dl)
WBC (10
9/L)
Monocytes (10
9/L)
PLTS (10
9/L)
BM-blasts (%)
12.9
5.72
0.70
74
5
11.2
4.09
1.5
56
2
Progression
AZA: 5-azacytidine (Vidaza, Celgene
TM), Hb: hemoglobin; WBC: white blood cells; PLTS: platelets; BM-Blast: bone marrow blast counts
activity in vitro and in vivo, reverting aberrant DNA 
methylation and increasing the expression of silenced 
genes,  leading  to  cellular  differentiation  and/or 
apoptosis.
3-4 Furthermore a direct cytotoxic effect has 
been  shown  in  cell  lines  treated  with  decitabine, 
partially  explaining  the  lack  of  correlation  between 
degree of demethylation and  response.
3-4
Case Report: We treated 3 CMML-2 patients (2 men 
and 1 woman) of a median age of 63 years (range 54-
69), and IPSS intermediate-2/high (normal caryotype, 1 
or  two  cytopenias  and  9-15%  bone  marrow 
blasts)(Table  1).  Patients  were  treated  with  5-
azacitidine  (Vidaza,  Celgene
TM)  at  75  mg/mq  for  7 
days at 14.2, 21.6 and 4 months from initial diagnosis. 
After 4 cycles of azacitidine, 2 patients achieved partial 
response and are in continuous partial response, with 
stable peripheral blood counts (Table 1) at 29 and 30 
cycles from treatment start and at 36 and 50 months 
from disease onset. Treatment has been well tolerated, 
with only mild gastrointestinal and cutaneous toxicity 
(WHO  grade  1).  One  54  year-old  patient,  after  a 
transient response to 5-Azacitidine with normalization 
of peripheral blood counts, progressed to AML after 4 
cycles,  underwent  allogenic  bone marrow 
transplantation and died  for  systemic infection  at  12 
months  from  CMML  diagnosis.  During  the  first 
azacitidine  cycle,  this  patient  had  developed  a  long 
period  of  pancytopenia,  complicated  by  acute 
respiratory  distress  due  to  Aspergillus  pneumonia, 
which recovered following anti-fungal treatment. AML 
progression  was  characterized  by  hyperleukocytosis 
and  acquisition  of  cytogenetic  abnormalities.  In  this 
patient, younger age, low hemoglobin levels and high 
peripheral  blood  monocyte  counts  at  CMML  onset, 
were  unfavourable  prognostic  factors,  according  to 
CMML stratified risk assessment.
6
Discussion: Efficacy of Azacitidine and Decitabine in 
the treatment of MDS has been confirmed by several 
national  and  international  clinical  trials  although  a 
protocol comparing efficacy of the two drugs has not 
been  performed  yet.  These  studies  demonstrated 
efficacy of hypomethylating agents compared to best 
supportive  care.
7-8 Azacitidine  in  particular, 
significantly prolonged median time to progression to 
acute myeloid leukemia or death and prolonged median 
overall  survival  compared  with  conventional  care 
regimens.
9-12 Hypomethylating agents have been only 
rarely  used  in  CMML  and  there  are  no  prospective 
studies with sufficient patient numbers in this disease.
A study by the MD Anderson reported the use of 
decitabine  in  19  elderly  CMML  patients,  with 
encouraging  results,  with  achievement  of  58% 
complete  remission  (CR)  and  11%  hematological 
improvement  (HI), resulting into  an overall response 
rate of 69%.
13 A retrospective review analyzing four 
phase  3  and  phase  2  trials  in  CMML  patients 
demonstrated 25%  overall  response rate  (CR  +  PR), 
with  additional  11% HI  and  39%  stable  disease, 
confirming  the  superiority  of  decitabine  over  best 
supportive  care.  Tolerability  was  good,  non 
hematologic  side  effects  were  minimal  and 
myelosuppression-associated  complications  were 
acceptable.
14 A recent paper on 38 CMML treated with 
Azacitidine  at  75  mg/mq/day  for  7  days  or  100 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
mg/mq/day for  5 days every 4 weeks, reported  39% 
overall response rate, with 11% CR, 3% PR and 25% 
HI  resulting  into  a  median  overall  survival  of  12 
months.
15 The  median  number  of  cycles  given  to 
achieve response was 2, with a median short duration 
of response of 6.5 months (range, 3 to over 50 months). 
Incorporation of azacitidine into DNA makes its effect 
S-phase dependent and requires two or more cycles of 
DNA  synthesis  to  alter  gene  transcription  and 
expression. Azacitidine also acts as a biologic response 
modifier  exerting  a  cytotoxic  effect  on  regulatory  T 
cells  or  other  modulatory  cells  which  may  inhibit 
hematopoiesis  in  MDS.  Thus,  the  response  is 
subjective  and  three  to  four  treatment  cycles  are 
necessary  before  the  effect  becomes  clinically 
apparent.  Moreover,  the  issue  of  the  best  treatment 
schedule is still controversial. Costa et al, tested a dose 
of 100 mg/mq/day for 5 consecutive days considering 
this approach more convenient and equal in efficacy.
15
Todate  there  are  no  specific  indications  on  the  best 
treatment schedule in CMML. Due to reversibility of 
hypomethylating  agents  effects  and  to  the  lack  of 
eradication of the malignant clone, treatment should be 
continued until response persists.
16
Our  findings  confirm  highly  favorable  response 
rates  to  azacitidine  therapy  in  high-risk  CMML 
patients, encouraging the application of the treatment 
in  this  subset  of  patients.  A  correct  risk  assessment 
requires  the  identification  of  new  molecular  and 
clinical  features  predictive  of  reponse  to 
hypomethylating agents, to make an effective patient-
targeted approach feasible.
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